The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

How SeaStar Medical Is Leveraging Its Breakthrough Medical Device Designation To Help Critically Ill Patients

By Meg Flippin Benzinga

SeaStar Medical seeks to bring organ-saving and life-saving solutions to critically ill patients who are suffering from hyperinflammation. The company's first therapy, QUELIMMUNE, which was approved by the U.S. Food and Drug Administration last year, is designed to treat pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition. 

SeaStar is also engaged in a trial evaluating the safety and efficacy of its second proprietary Selective Cytopheretic Device (SCD) therapeutic in adults with AKI. That trial already has half of the adults enrolled and represents a market opportunity Schlorff says is worth about $4.5 billion a year. SeaStar, which has received several Breakthrough Device Status designations from the FDA, is betting its therapy can be broadly applied to many serious, life-threatening conditions. 

Watch the full interview here: 
https://www.youtube.com/watch?v=zREelPU2KIk

Featured image by Annie Spratt on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.